{"filings":[{"id":1258877,"accession_number":"0001213900-26-071745","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-06-25T11:31:00+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex granted US patent covering IHL-42X for obstructive sleep apnea through 2040","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["USPTO granted patent for IHL-42X composition and methods for OSA; baseline expiry 9 July 2040.","Company exploring patent term extension after potential FDA approval to lengthen exclusivity.","IHL-42X has FDA Fast Track designation, positive Phase II data; DReAMzz study nearing patient recruitment with site IRB approvals and DEA registrations.","CEO states patent validates IHL-42X as differentiated asset targeting billion-person OSA market with poor adherence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":954918,"accession_number":"0001213900-26-067081","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-06-10T11:30:39+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex receives A$6M R&D tax refund; expects another A$5.1M in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received A$6,039,162 under Australian Government's R&D Tax Incentive Program for FY25.","Expects additional ~A$5.1M later in 2026, total >A$11.1M non-dilutive capital received this year.","Non-dilutive refund strengthens balance sheet, supports clinical programs (IHL-42X, PSX-001) and share repurchase.","CEO states refund obtained without issuing shares; company remains debt-free."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927637,"accession_number":"0001213900-26-066526","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-06-09T11:30:47+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex initiates research coverage by Alliance Global Partners with BUY rating, $18 PT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alliance Global Partners (AGP) initiates coverage with BUY rating and $18.00 price target as of June 8, 2026.","Analyst James Molloy, AGP Managing Director and Senior Biotechnology Analyst, authored the report.","Incannex's lead programs: IHL-42X for obstructive sleep apnoea (DReAMzz study) and PSX-001 synthetic psilocybin for generalized anxiety disorder.","AGP has received compensation from Incannex for providing investment banking services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77683,"accession_number":"0001213900-26-056227","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-05-14T11:30:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex commences DReAMzz study of IHL-42X for obstructive sleep apnea","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 14 clinical trial sites identified; site contracting underway; import/export permits secured.","Study is a crossover dose optimization to de-risk Phase III pathway for IHL-42X.","Previously reported Phase II RePOSA showed statistically significant AHI reductions and improved oxygenation.","FDA granted Fast Track designation for IHL-42X in OSA.","Manufacturing of clinical trial supply completed; global distribution partner onboarded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22484,"accession_number":"0001213900-26-054725","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-05-12T11:30:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X for Obstructive Sleep Apnea","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Awarded 'Best New Technology Solution for Drug Development' in 10th annual MedTech Breakthrough Awards program.","IHL-42X is a fixed-dose combination of dronabinol and acetazolamide targeting key drivers of OSA.","Phase 2 RePOSA trial showed statistically significant reductions in AHI and improvements in oxygenation, sleep quality, and fatigue.","CEO Joel Latham noted the award validates progress and potential to redefine OSA treatment paradigm.","Recognition comes as Incannex advances IHL-42X toward late-stage development and explores strategic opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96459,"accession_number":"0001213900-26-046408","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex Healthcare PSX-001 aligns with Trump Executive Order accelerating psychedelic mental health treatments","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["White House Executive Order (April 18, 2026) directs FDA to prioritize psychedelic compounds with Breakthrough Therapy designations and creates Right to Try pathways.","PSX-001 Phase 2 for GAD: 12.8-point HAM-A reduction vs 3.6 placebo (p<0.0001), 44% response rate, 27% remission rate, no serious adverse events.","Company has over $70M cash, no debt; active U.S. IND; views Executive Order as reducing regulatory and commercial risk for psilocybin class.","PSX-001 targets GAD affecting ~6.8M in U.S. and 280M globally; Phase 2 had single discontinuation across 73 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110376,"accession_number":"0001213900-26-035161","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex reactivates share repurchase program, citing undervaluation and $75M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board reinitiated buyback after inactivity; purchases executed over past two trading days.","Company holds ~$75M cash and no debt; $18.5M remains available under the program.","CEO Joel Latham states current market valuation does not reflect balance sheet or pipeline progress.","Repurchases will be opportunistic based on market conditions and capital needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110375,"accession_number":"0001213900-26-033842","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex partners with AASM Foundation, sponsors junior investigator sleep apnea grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with AASM Foundation Corporate Recognition Program to support sleep apnea research.","Sponsors a Focused Projects Grant for Junior Investigators in Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026.","IHL-42X Phase 2 DReAMzz study patient dosing expected within coming months; Phase 3 pathway defined.","Previous milestones: positive Phase 2 results, FDA Fast Track designation, and establishment of Clinical Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110374,"accession_number":"0001213900-26-029761","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incannex reports ~$75M cash, no debt; advances IHL-42X sleep apnea program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash position ~$75M, no debt; market cap ~$46M, resulting in negative enterprise value.","Financing led by healthcare-focused institutional investors funds DReAMzz dose-optimization study for IHL-42X.","Company expects to start dosing DReAMzz study within months; Phase 2 results showed significant OSA improvements.","PSX-001 for generalized anxiety disorder progressing with open IND and clinical advisory board.","Board-approved share buyback program remains available for shareholder value delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110373,"accession_number":"0001213900-26-028661","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Incannex regains Nasdaq minimum bid price compliance; listing overhang removed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nasdaq confirmed compliance after IXHL closed at ≥$1.00 for 11 consecutive business days through March 13, 2026.","Company had previously disclosed bid price deficiency in April and October 2025; matter is now closed.","CEO Joel Latham highlighted $75M cash, no debt, and pipeline progress (IHL-42X, PSX-001).","Regaining compliance ensures continued listing on Nasdaq Capital Market, removing a technical overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110372,"accession_number":"0001213900-26-026645","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Incannex Healthcare announces $10M registered direct offering of 2M shares and warrants at $5.00/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 2,000,000 shares (or equivalents) and 2,000,000 common warrants; combined price $5.00 per share and accompanying warrant.","Gross proceeds ~$10M; warrants exercisable at $6.50 for 5 years; potential additional $13M if fully exercised.","Proceeds expected to fund Phase 2 DReAMzz study for IHL-42X; prior cash on hand reserved for Phase 3 anticipated in H2 2027.","Company terminated its at-the-market facility and does not intend to use ATM near term.","Offering expected to close March 13, 2026; Curvature Securities acted as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110371,"accession_number":"0001213900-26-026644","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.02","7.01","8.01","9.01"],"status":"ready","headline":"Incannex terminates $108.4M ATM sales agreement; announces enhanced Phase 2 dose-optimisation study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutually terminated Sales Agreement with Curvature Securities and A.G.P., effective March 11, 2026.","Raised aggregate gross proceeds of ~$108.4M under the agreement prior to termination.","Issued press release announcing enhanced Phase 2 dose-optimisation study (likely IHL-42X for OSA).","Corporate presentation confirms cash position of ~$70M as of December 2025.","Pipeline includes Phase 2/3 trials for OSA, GAD, and RA with positive data reported August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110370,"accession_number":"0001213900-26-020127","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Incannex Healthcare files for 1-for-30 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-30 effective 4:01 p.m. ET Feb 26, 2026; post-split trading begins Feb 27 under same ticker IXHL.","Outstanding shares reduced from ~358M to ~11.9M; authorized shares unchanged.","No fractional shares; rounding up to next whole share, cash not paid.","Purpose is to increase per-share trading price to regain Nasdaq minimum bid price compliance.","Stockholders approved at special meeting on May 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110369,"accession_number":"0001213900-26-009160","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare Appoints Three New Members to Clinical Advisory Board for PSX-001 Program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Murray B. Stein, MD, MPH (UCSD); Andrew Cutler, MD (SUNY Upstate); and Amir Kalali, MD to Clinical Advisory Board.","Drs. Stein, Cutler, and Kalali bring expertise in psychiatry, neurobiology, psychopharmacology, and clinical development.","CAB will advise on PSX-001 clinical trial design, endpoint selection, regulatory engagement, and development strategy.","CMO Dr. Lou Barbato stated the appointments support disciplined execution and risk management for PSX-001 program.","Incannex Healthcare (IXHL) is a Nasdaq-listed clinical-stage biopharma developing innovative combination therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110368,"accession_number":"0001213900-26-006448","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare forms Clinical Advisory Board for PSX-001 anxiety program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical Advisory Board (CAB) established to support PSX-001 development for generalized anxiety disorder.","CAB will advise on trial design, endpoint selection, regulatory engagement, and strategic approach.","Inaugural members: Dr. C. Neill Epperson, Dr. Charles B. Nemeroff, and Dr. Alan F. Schatzberg.","CMO Dr. Lou Barbato says CAB will help inform key development decisions and support shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110367,"accession_number":"0001213900-26-004866","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Incannex Healthcare annual meeting elects directors and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 119,550,295 shares (34.38%) present at Jan 15, 2026 annual meeting.","Dr. George Anastassov re-elected with 55,032,850 votes for; Robert Clark with 56,220,279.","Ratification of Grant Thornton Audit Pty Ltd as auditor approved: 110,346,963 for, 7,877,386 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110366,"accession_number":"0001213900-26-004488","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex wins R&D award for obstructive sleep apnea drug IHL-42X","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Recognized in Respiratory Disorders category of 2025 Clinical Trials Arena Excellence Awards.","IHL-42X is an oral fixed-dose combination (dronabinol + acetazolamide) for moderate-to-severe OSA.","Award highlights Incannex's research-driven approach to address unmet needs in device-based therapy non-adherence.","CEO Joel Latham states award underscores science-driven approach as IHL-42X advances into late-stage development.","Company also progressing pipeline programs IHL-675A (rheumatoid arthritis) and PSX-001 (anxiety)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110365,"accession_number":"0001213900-26-004158","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex reports >$70M cash, two positive Phase 2 readouts, FDA Fast Track; outlines 2026 outlook","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents >$70M, providing operating runway into 2027.","IHL-42X (OSA) Phase 2 RePOSA: up to 83% AHI reduction; FDA Fast Track designation.","PSX-001 (GAD) Phase 2: statistically significant improvement on HAM-A vs placebo.","Completed $12.5M private placement; eliminated all Series A warrants.","Authorized $20M share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126966,"accession_number":"0001213900-25-123041","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Incannex Healthcare adjourns 2025 annual meeting to Jan 15, 2026 due to broker non-vote on auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No quorum at Dec 18, 2025 annual meeting due to Auditor Ratification Proposal being misclassified as non-routine by transfer agent.","Meeting adjourned to Jan 15, 2026 at 11:00 a.m. Gulf Standard Time; reconvenes virtually via www.meetnow.global/MD59M9U.","Company seeks reclassification of proposal as routine to allow broker discretionary voting on street-name shares.","Proxies already submitted remain valid unless revoked; additional proxy solicitation will continue during adjournment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126965,"accession_number":"0001213900-25-117571","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track designation to Incannex's IHL-42X for obstructive sleep apnea","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track designation for Incannex's IHL-42X for obstructive sleep apnea (OSA).","Phase 2 RePOSA study showed up to 83% reduction in AHI; safety and patient-reported outcomes positive.","Fast Track enables rolling NDA submission, more FDA interaction, and potential Accelerated Approval.","Incannex expects to receive FDA feedback on Phase 2 data and map path to late-stage development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126964,"accession_number":"0001213900-25-103780","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex updates on Phase 2 results for IHL-42X and PSX-001; ATM shares unchanged since Aug 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IHL-42X Phase 2 OSA trial showed up to 83% reduction in AHI; 57.6% of participants reported improvement (78.6% low dose).","PSX-001 Phase 2 GAD trial met primary endpoint HAM-A and multiple secondary measures with sustained relief over 11 weeks, no SAEs.","ATM facility not utilized since Aug 28, 2025; total shares outstanding unchanged at 347,705,507.","Company prioritizing FDA engagement for pivotal development of IHL-42X and PSX-001, and exploring partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126963,"accession_number":"0001213900-25-100985","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex gets 180-day Nasdaq extension to April 20, 2026 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted Incannex until April 20, 2026 to maintain $1.00 closing bid for 10 consecutive days.","Extension follows Incannex meeting all other listing criteria and providing reverse stock split intent.","CEO notes two Phase 2 clinical data packages delivered in 2025 and strong cash position.","Company will monitor share price and take actions to regain compliance within the extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126962,"accession_number":"0001213900-25-100980","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Incannex Healthcare gets Nasdaq bid price compliance extension to April 20, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received second 180-day grace period from Nasdaq until April 20, 2026 to regain $1 minimum bid price.","Failed bid price requirement; transferred to Nasdaq Capital Market on July 10, 2025.","Must close at $1 or above for 10 consecutive business days during extension to comply.","Company intends to cure deficiency via reverse stock split if necessary.","Listing on Nasdaq Capital Market continues; no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143766,"accession_number":"0001213900-25-080509","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex reports positive Phase 2 results for PSX-001 in Generalized Anxiety Disorder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Psi-GAD (PSX-001) achieved a 12.8-point HAM-A reduction vs. 3.6 for placebo (p<0.0001) over 11 weeks.","44.1% of patients had clinical response (≥50% HAM-A reduction) and 27% achieved full remission (HAM-A ≤7).","GAD-7 scores fell 7.4 points, SDS improved 6.0 points, PHQ-9 dropped 3.9 points, all statistically significant.","No serious adverse events reported; only one subject withdrew from the 73-participant trial.","Incannex plans a multi-jurisdiction Phase 2 trial and is exploring strategic partnerships for PSX-001."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143765,"accession_number":"0001213900-25-079600","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare authorizes $20M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repurchase of up to $20M of common stock via open market or negotiated transactions.","Program may use Rule 10b5-1 plans and complies with Rule 10b-18.","CEO Joel Latham states buyback reflects confidence in pipeline and current undervaluation.","Timing and amount depend on market conditions and available capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143764,"accession_number":"0001213900-25-073321","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex reports positive Phase 2 data for IHL-42X in obstructive sleep apnoea; AHI reductions up to 83%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Low- and high-dose IHL-42X achieved statistically significant reduction in AHI vs placebo (p<0.05); max AHI reduction 83% in high-dose group.","41.2% of high-dose group achieved >30% AHI reduction; 14.7% had >50% reduction; no reduction in REM sleep.","89.5% of patients reporting improvement described change as meaningful; benefits included improved sleep quality and reduced daytime fatigue.","No serious adverse events; treatment-emergent adverse effects infrequent, mild/moderate; drug well tolerated.","CEO notes share price volatility, states company is well-capitalized and considering strategic levers including anti-dilution measures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143763,"accession_number":"0001213900-25-069638","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex states no plans to fully utilise ATM near term; cash ~$50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash balance ~US$50M; no plan to fully utilise ATM in near term; sold only 1.97% of volume on Jul 30.","Company sold ~9.2M shares on Jul 30 under ATM, representing 1.97% of daily trading volume; previous use Jul 17.","CEO Joel Latham: ATM provides long-term flexibility; committed to minimising dilution for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143762,"accession_number":"0001213900-25-068954","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex reports positive Phase 2 results for IHL-42X in obstructive sleep apnea; AHI reduced up to 83%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IHL-42X reduced AHI up to 83% (high-dose) and 79% (low-dose) from baseline; 41.2% of high-dose patients achieved >30% reduction.","Statistically significant improvements in PGI-C sleep related impairment, fatigue, ODI, and patient-reported outcomes (FOSQ-10, ESS, PROMIS).","No serious adverse events reported; treatment-emergent adverse effects infrequent, mostly mild/moderate.","Preparing End-of-Phase 2 meeting with FDA; advancing toward commercial readiness and Phase 3 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143761,"accession_number":"0001213900-25-067474","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex appoints Dr. Gamaldo to OSA advisory board; Phase 2 data due next week","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Charlene E. Gamaldo (Johns Hopkins professor) joins IHL-42X Obstructive Sleep Apnea Clinical Advisory Board.","Phase 2 data readout for IHL-42X expected next week, per CMO Dr. Lou Barbato.","Gamaldo has joint appointments in neurology, psychiatry, nursing, anesthesiology, and public health.","She has authored >120 scholarly works and received multiple sleep medicine leadership awards.","Appointment reflects Incannex's growing confidence in IHL-42X and commitment to scientific rigor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143760,"accession_number":"0001213900-25-067374","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare increases ATM capacity by $100 million for financial flexibility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase ATM offering capacity by up to $100 million in common shares.","ATM conducted under Amended and Restated Sales Agreement with A.G.P. and Curvature dated May 28, 2025.","Company is not obligated to issue any shares; any sales will depend on market conditions and discretion.","Legal opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. attached regarding share legality."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162011,"accession_number":"0001213900-25-056901","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex appoints Dr. Kirsch to OSA board; Phase 2 data due July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Douglas B. Kirsch, M.D., FAAN, FAASM to IHL-42X Obstructive Sleep Apnea Clinical Advisory Board.","Dr. Kirsch is Medical Director of Atrium Health Sleep Medicine and former President of the American Academy of Sleep Medicine.","Company expects to report topline Phase 2 data from the U.S. RePOSA study in July 2025.","Phase 3 initiation for IHL-42X targeted for later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162010,"accession_number":"0001213900-25-055407","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex achieves database lock for RePOSA Phase 2 trial of IHL-42X; top-line results expected July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Database lock achieved June 16, 2025, on schedule; final statistical analysis begins.","Top-line results from Phase 2 trial of IHL-42X for obstructive sleep apnoea expected July 2025.","IHL-42X is a first-in-class oral therapy for OSA; no approved oral pharmacological treatment exists.","Trial evaluates IHL-42X in moderate to severe OSA patients unable/unwilling to use CPAP.","Over 900 million people affected by OSA worldwide; IHL-42X aims to address underserved patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162009,"accession_number":"0001213900-25-054952","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare forms 50:50 JV with Mind Medicine Australia for psychedelic therapy clinic","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["JV creates 'Mind Medicine Australia Clinics' to operate a clinic in Melbourne.","JV aims to reduce treatment costs and more than triple patient capacity for PTSD and depression.","Patient intake expected to begin shortly in response to strong early demand.","MMA led 2023 regulatory rescheduling of psilocybin and MDMA for clinical use in Australia.","Incannex CEO cites alignment with long-term shareholder value and commercialization model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162008,"accession_number":"0001213900-25-053995","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Incannex Healthcare files to transfer listing from Nasdaq Global Market to Capital Market to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntary transfer from Nasdaq Global Market to Nasdaq Capital Market announced June 11, 2025.","Move aims to address continued listing requirements; prior non-compliance disclosed in Jan and Apr 2025 8-Ks.","If accepted, common stock will continue trading under symbol IXHL on Nasdaq Capital Market.","Application subject to Nasdaq acceptance; company may still face delisting if compliance not maintained.","Risks include potential failure to regain bid price compliance even after transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162007,"accession_number":"0001213900-25-053588","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex cancels all Series A Warrants, eliminating 347.2M shares of potential dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cancelled remaining 172M Series A Warrants for $12.2M via ATM facility; combined with earlier tranche removes 347.2M shares.","CEO Joel Latham says cancellation eliminates significant dilution ahead of Phase 2 RePOSA topline data for IHL-42X in July 2025.","IHL-42X is a potential first-in-class oral therapy for obstructive sleep apnea, a condition with no FDA-approved drug."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162006,"accession_number":"0001213900-25-050327","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex adds four OSA experts to IHL-42X advisory board; Phase 2 data July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Scott Sands, Ali Azarbarzin, Lora McGill, and Nancy Collop to the IHL-42X Clinical Advisory Board.","Company expects to announce IHL-42X Phase 2 topline data in July 2025.","Phase 3 US study planned to start later in 2025.","IHL-42X is an oral once-daily treatment for obstructive sleep apnea (OSA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162005,"accession_number":"0001213900-25-048507","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare advances IHL-42X RePOSA trial to Phase 3 after FDA clearance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared Phase 3 protocol for IHL-42X under IND; trial for obstructive sleep apnea (OSA) with no approved oral therapy.","Phase 3 will be US-only, leveraging Phase 2 infrastructure; ~20 existing sites roll over, 10 new sites added.","Study design: randomized, placebo-controlled, 12 months, including head-to-head against monotherapy components.","Primary endpoint: change in Apnea-Hypopnea Index (AHI); top-line Phase 2 results due in coming weeks.","CEO cites potential to become first FDA-approved oral therapy for OSA; commercial discussions underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162004,"accession_number":"0001213900-25-048001","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex cancels 172M Series A warrants, eliminating up to 347.2M shares from dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement to cancel remaining 172M Series A warrants; cancellation payment up to $12.2M.","Combined with earlier cancellation (175.2M), total elimination of up to 347.2M potential shares.","Move ahead of Phase 2 RePOSA trial data for IHL-42X in sleep apnea expected July 2025.","CEO Joel Latham cites strengthening capital structure and proactive dilution management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162003,"accession_number":"0001213900-25-047988","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","1.02","5.02","5.07","5.03","9.01"],"status":"ready","headline":"Incannex Healthcare increases authorized shares 8x, approves reverse split up to 1:50, expands ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 100M to 800M; shareholders approved at May 27 special meeting.","Reverse stock split authorized at ratio between 1:2 and 1:50, with board discretion to abandon.","Entered second warrant cancellation letter agreements; up to $12.3M net proceeds could cancel remaining Series A warrants to zero.","Amended ATM sales agreement adding Curvature Securities as agent; increased potential issuance by up to $50M additional shares.","Shareholders approved amendment to 2023 equity plan adding 2.7M shares and evergreen provision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162002,"accession_number":"0001213900-25-045651","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex cancels 50.4% of Series A Warrants, reduces potential dilution from 175M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $16.7M gross via ATM; used $12.5M to cancel up to 5,841,038 Series A Warrants (50.4%).","Cancellation eliminates overhang that could have caused issuance of 175.2M additional shares.","CEO Joel Latham says move puts shareholders in stronger position ahead of Phase 2 IHL-42X data.","Company plans further capital structure improvements; views this as signal of long-term value focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162001,"accession_number":"0001213900-25-045641","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Healthcare increases ATM offering capacity by up to $2.5M after $16.8M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 20, 2025, raising maximum shares under ATM to $2,514,214.","Approximately $16,768,095 in shares already sold under the Sales Agreement with A.G.P/Alliance Global Partners.","New shares are common stock, par value $0.0001, issued under existing Sales Agreement dated April 7, 2025.","Legal opinion from Mintz, Levin attached regarding legality of share issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162000,"accession_number":"0001213900-25-044600","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex enters agreements to reduce up to 50.4% of Series A warrant shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First ~$12.5M net proceeds from ATM to cancel up to 5,833,333 underlying shares (adjustable to 175M).","Warrant exercise requires stockholder approval at May 27, 2025 special meeting.","CEO Joel Latham cites commitment to advancing IHL-42X for obstructive sleep apnea.","Agreements signed on May 15, 2025; potential reduction of up to 50.4% of warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161999,"accession_number":"0001213900-25-044002","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Incannex Healthcare modifies Series A warrants, reduces potential share count via cancellation payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $12.5M in net proceeds from ATM offering to be paid as Warrant Cancellation Payment to Series A holders.","If $12.5M paid, warrant shares reduced from 11,574,090 to 5,740,757 (before price adjustments).","Warrant holders waived reserve requirements and $1.08 price floor until stockholder approval.","Special meeting for stockholder approval scheduled for May 27, 2025; no guarantee of approval.","Company not obligated to issue shares under Sales Agreement; ATM proceeds uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161998,"accession_number":"0001213900-25-043706","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex Q3 FY2025 net loss $3.97M, cash $6.71M, IHL-42X Phase 2 dosing done","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.97M for quarter ended March 31, 2025, vs $6.03M same quarter last year.","Cash and equivalents $6.71M as of March 31, up from $2.09M at Dec 31, 2024, after $12.5M private placement.","Completed dosing of >120 patients in Phase 2 portion of RePOSA study for IHL-42X (OSA); topline data expected July 2025.","Reported positive PK/safety study results for IHL-42X; both active components bioavailable, comparable to reference drugs.","Formed OSA Clinical Advisory Board; appointed Alison Wimms (ResMed) as member."],"consensus_eps_estimate":-0.9449,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":86000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161997,"accession_number":"0001213900-25-042962","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex completes Phase 2 dosing of IHL-42X for OSA; topline data expected July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed patient dosing in Phase 2 portion of RePOSA study on May 8, 2025; end-of-study follow-up by May 17, 2025.","Topline results from Phase 2 expected in July 2025; end-of-Phase 2 FDA meeting to follow.","Phase 3 plan: 440 patients exclusively at U.S. sites; decision supported by site and patient enthusiasm.","Incannex engaged in preliminary commercial discussions for IHL-42X ahead of data readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161996,"accession_number":"0001213900-25-035636","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["3.01","8.01","3.02"],"status":"ready","headline":"Incannex receives Nasdaq bid price deficiency notice; cure period until Oct 20, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of IXHL common stock below $1.00 for 30 consecutive trading days.","Nasdaq granted 180-day compliance period ending October 20, 2025.","If not compliant, Company may transfer to Nasdaq Capital Market for additional 180-day cure.","Lead asset IHL-42X (obstructive sleep apnea) Phase 2 top-line data expected before end of H1 2025.","Company evaluating options including reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161995,"accession_number":"0001213900-25-029418","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Incannex Healthcare enters ATM sales agreement for up to $16.8M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with A.G.P./Alliance Global Partners; 3.0% commission on gross proceeds.","Maximum aggregate sales price of $16,768,099 under the ATM facility.","Issuance restricted to $1.08 minimum per share until 30 days after release of March 2025 private placement.","Only 7 shares can be issued before stockholder approval; Company unlikely to use ATM in near term.","Company filed prospectus supplement dated April 7, 2025 for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161994,"accession_number":"0001213900-25-028373","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incannex completes Phase 2 enrollment in RePOSA trial of IHL-42X for OSA; topline data expected H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment of >120 patients across 11 U.S. sites in Phase 2 dose-finding portion of RePOSA Phase 2/3 study of IHL-42X for OSA.","Topline Phase 2 clinical data expected in first half 2025; results will determine optimal dose for Phase 3.","Phase 3 expansion planned with ~440 patients across four treatment arms over 52 weeks to support future FDA NDA submission.","IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide targeting physiological pathways of OSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180057,"accession_number":"0001213900-25-024752","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Incannex repays $3.85M convertible debenture, terminates Arena financing agreements","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid outstanding 10% OID Senior Secured Convertible Debenture with $3,851,111 cash payment on March 13, 2025.","Debenture Purchase Agreement, Security Documents, and Equity Line Purchase Agreement with Arena entities terminated except for indemnification and registration rights.","Debenture Warrant (453,749 shares) and ELOC Warrant (585,000 shares) remain in effect; exercise prices adjusted after private placement closed March 10, 2025.","The repayment eliminates a convertible obligation, reducing potential dilution and secured debt on balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180056,"accession_number":"0001213900-25-022279","cik":1873875,"company_name":"Incannex Healthcare Inc.","ticker":"IXHL","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Incannex prices $12.5M private placement at $1.08/share to fund OSA trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $12.5M from 11.57M shares at $1.08 plus Series A warrants at $2.16.","Net proceeds ~$11.3M after placement agent fees and expenses.","Funds IHL-42X Phase 2/3 OSA study completion and Phase 3 expansion.","Proceeds also repay outstanding convertible debentures and for working capital.","Transaction closed March 10, 2025; R.F. Lafferty as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41756292.92307693,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-03-10T23:59:59+00:00|180056"}